Angelini Pharma acquires Catalyst Pharmaceuticals

Angelini Pharma is set to acquire Catalyst Pharmaceuticals for $4.1 billion, a strategic move that positions the Italian company as a significant player in the U.S. rare disease market. The acquisition includes a portfolio of neuromuscular and neurological therapies, marking a pivotal step in Angelini's plans to expand beyond its traditional European base.

Under the terms of the deal, Angelini will pay $31.50 per share in cash, representing a 21% premium over Catalyst's closing share price on April 22, 2026, and a 28% premium over its 30-day volume-weighted average price. The transaction has received unanimous board approval from both companies and is expected to conclude in the third quarter of 2026, pending Catalyst's shareholder vote and customary regulatory approvals. The financing for the acquisition will consist of a blend of cash and debt, coordinated by BNP Paribas and involving Blackstone funds alongside other international partners.

Catalyst Pharmaceuticals brings a suite of three U.S.-approved treatments: Firdapse, Agamree, and Fycompa, which target rare neuromuscular and neurological conditions. CEO Rich Daly highlighted the transaction as a transformative juncture for Catalyst, emphasizing the enhanced global reach and the creation of a robust platform for rare disease therapies as key benefits. Daly noted that the deal delivers immediate and substantial cash value to Catalyst shareholders.

Strategically, this acquisition accelerates Angelini’s shift from a regional to a global company, specifically in the central nervous system (CNS) and rare disease markets. Integrating Catalyst’s assets and established U.S. infrastructure will enable Angelini to build a strong North American presence, complementing its European portfolio, which includes products like Ontozry. This transaction aligns with Angelini’s broader strategy of bolstering its CNS focus, supported by a history of partnerships such as its venture with Blackstone Life Sciences in GRIN Therapeutics.

The acquisition reflects ongoing consolidation in the pharmaceutical sector, particularly in rare disease treatment, where specialized therapies command premium valuations. As Angelini extends its market reach, competitors in the rare disease and neurology segments may need to reassess their strategic positions. With global pharmaceutical companies increasingly seeking entry into niche markets, the deal underscores the importance of having a diverse portfolio and geographic footprint.

Looking ahead, the primary focus will be on securing necessary regulatory approvals and shareholder consent, with the anticipated closing in late 2026. Successful integration of Catalyst’s operations and products will be critical for Angelini as it ventures further into global markets.